WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for KPTI

Based on 3 analysts offering 12 month price targets for Karyopharm Therapeutics Inc.
Min Forecast
$3.00+300%
Avg Forecast
$5.00+566.67%
Max Forecast
$7.00+833.33%

Should I buy or sell KPTI stock?

Based on 3 analysts offering ratings for Karyopharm Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KPTI stock forecasts and price targets.

KPTI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-07
lockedlocked$00.00+00.00%2024-08-07
lockedlocked$00.00+00.00%2024-08-07

1 of 1

Forecast return on equity

Is KPTI forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is KPTI forecast to generate an efficient return on assets?
Company
-19.52%
Industry
26.35%
KPTI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KPTI earnings per share forecast

What is KPTI's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.93
Avg 2 year Forecast
-$0.66
Avg 3 year Forecast
-$0.35

KPTI revenue forecast

What is KPTI's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$152.9M+4.96%
Avg 2 year Forecast
$182.9M+25.54%
Avg 3 year Forecast
$231.0M+58.59%
KPTI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KPTI revenue growth forecast

How is KPTI forecast to perform vs Biotechnology companies and vs the US market?
Company
15.97%
Industry
34.51%
Market
9.31%
KPTI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KPTI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KPTI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KPTI$0.75$5.00+566.67%Buy
COYA$6.14$16.67+171.45%Strong Buy
CTMX$1.21$5.77+377.11%Strong Buy
CASI$6.89$6.00-12.92%Buy
EPRX$2.70N/AN/A
View Top Biotech Stocks

Karyopharm Therapeutics Stock Forecast FAQ

Is Karyopharm Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KPTI) stock is to Buy KPTI stock.

Out of 3 analysts, 0 (0%) are recommending KPTI as a Strong Buy, 3 (100%) are recommending KPTI as a Buy, 0 (0%) are recommending KPTI as a Hold, 0 (0%) are recommending KPTI as a Sell, and 0 (0%) are recommending KPTI as a Strong Sell.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.

What is KPTI's earnings growth forecast for 2024-2026?

(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.58%.

Karyopharm Therapeutics's earnings in 2024 is -$89,913,000.On average, 2 Wall Street analysts forecast KPTI's earnings for 2024 to be -$115,955,823, with the lowest KPTI earnings forecast at -$134,658,375, and the highest KPTI earnings forecast at -$97,253,271. On average, 4 Wall Street analysts forecast KPTI's earnings for 2025 to be -$82,291,229, with the lowest KPTI earnings forecast at -$119,696,334, and the highest KPTI earnings forecast at -$42,392,452.

In 2026, KPTI is forecast to generate -$44,050,744 in earnings, with the lowest earnings forecast at -$53,613,983 and the highest earnings forecast at -$37,405,104.

What is KPTI's revenue growth forecast for 2024-2026?

(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 15.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Karyopharm Therapeutics's revenue in 2024 is $145,668,000.On average, 4 Wall Street analysts forecast KPTI's revenue for 2024 to be $19,063,511,406, with the lowest KPTI revenue forecast at $18,403,311,316, and the highest KPTI revenue forecast at $19,486,812,503. On average, 4 Wall Street analysts forecast KPTI's revenue for 2025 to be $22,800,530,693, with the lowest KPTI revenue forecast at $19,325,970,555, and the highest KPTI revenue forecast at $26,148,661,579.

In 2026, KPTI is forecast to generate $28,803,925,250 in revenue, with the lowest revenue forecast at $26,525,206,296 and the highest revenue forecast at $31,402,831,897.

What is KPTI's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: KPTI) forecast ROA is -19.52%, which is lower than the forecast US Biotechnology industry average of 26.35%.

What is KPTI's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KPTI price target, the average KPTI price target is $5.00, with the highest KPTI stock price forecast at $7.00 and the lowest KPTI stock price forecast at $3.00.

On average, Wall Street analysts predict that Karyopharm Therapeutics's share price could reach $5.00 by Aug 7, 2025. The average Karyopharm Therapeutics stock price prediction forecasts a potential upside of 566.67% from the current KPTI share price of $0.75.

What is KPTI's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: KPTI) Karyopharm Therapeutics's current Earnings Per Share (EPS) is -$0.83. On average, analysts forecast that KPTI's EPS will be -$0.93 for 2024, with the lowest EPS forecast at -$1.08, and the highest EPS forecast at -$0.78. On average, analysts forecast that KPTI's EPS will be -$0.66 for 2025, with the lowest EPS forecast at -$0.96, and the highest EPS forecast at -$0.34. In 2026, KPTI's EPS is forecast to hit -$0.35 (min: -$0.43, max: -$0.30).

What is KPTI's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: KPTI) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.